Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New screening tool aims to catch diabetic nerve damage early

NCT ID NCT07163000

Diagnosis Sponsor: Weill Cornell Medical College in Qatar Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study tests a short questionnaire called ACT to see if it can accurately detect nerve damage in the feet and legs of people with diabetes. Researchers will compare it to standard screening tools and an eye test that looks at tiny nerve fibers. The goal is to find a simple, non-invasive way to diagnose peripheral neuropathy earlier.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ACT questionnaire
What this could lead to
If successful, this could provide a simple, low-cost way to catch diabetic nerve damage earlier, helping prevent complications.
What could go wrong
This is a small, early-stage validation study, not a treatment trial. The questionnaire may not prove accurate enough for widespread use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

150 people

The number who actually took part.

Started

May 2025

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Participants attending the outpatients clinic at the diabetes center

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with diabetes (T1DM and T2DM) * Age ≥18 * Able to provide consent. * Able to sit still for corneal confocal microscopy Exclusion Criteria: * Failure to provide informed consent * Participants with a history of ocular trauma or previous ocular surgery in the preceding 6 months, are allergic to oxybuprocaine or local anesthetics or unable to cooperate by holding still or placing their chin on an optical device * Other causes of peripheral neuropathy: vitamin B12 deficiency; hypothyroidism; myeloma. * Cognitively impaired participants * Pregnant women * Nursing women

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetes (DM) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

diabetes mellitus neuropathy, painful peripheral nervous system disorder peripheral neuropathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diabetes (DM) Painful neuropathy Peripheral neuropathy

Contacts and locations

Locations

  • Weill Cornell Medicine-Qatar

    Doha, 24144, Qatar

More trials for these conditions

Other studies related to the condition(s) this trial covers.